Social Determinants of Health and Clinical Burden in Narcolepsy: A Retrospective Cohort Analysis

Anan Zhou, MPH¹; Katarina Irwin, MS²; Sarah C. Markt, ScD, MPH³; Jon Michael Stroh²; Jiayuan Wang²; Martin Zagari, MD²; Caroleen Drachenberg, PhD, MSPH³; Jessica K. Alexander, PhD³; Marisa Whalen, PharmD³; Junko Saber, MBA²; Barbara Hutchinson, MD, PhD⁴ ¹Genesis Research Group, Hoboken, NJ, USA; ²Innopiphany, LLC, Irvine, CA, USA; ³Jazz Pharmaceuticals, Palo Alto, CA, USA; ⁴Chesapeake Cardiac Care, Bowie, MD, USA


Introduction

- Although the clinical comorbidity burden of narcolepsy, a central disorder of hypersomnolence characterized by excessive daytime sleepiness, is well documented,1 the impact of social determinants of health (SDoH) on this population remains poorly understood
- The National Institutes of Health (NIH) launched the All of Us Research Program as a nationwide initiative to create a database reflecting the increasingly diverse US population²
- The All of Us Database is a comprehensive resource that includes deidentified data from electronic health records (EHRs) and participant surveys, including information on demographics, overall health, lifestyle, and a specific survey assessing SDoH factors

Objective


• To describe demographic and clinical characteristics of individuals with narcolepsy, focusing on SDoH and health disparities

Methods




- A retrospective, observational study was conducted using EHR and survey data from the All of Us Research Program (1/1/2007–7/31/2022)
- Individuals with narcolepsy were required to have 1 Systematized Nomenclature of Medicine (SNOMED) code for narcolepsy (1/1/2009–1/31/2022); index was defined as the earliest diagnosis date
- Participants without narcolepsy were selected using risk set sampling and matched 3:1 to those with narcolepsy on age and year at main survey completion, sex, year and month of earliest EHR encounter, available time in the EHR, and SDoH survey completion status
- SDoH factors, including education level, employment status, disability status, and healthcare access, were obtained from core surveys (The Basics, Overall Health, and Lifestyle)
- Additionally, measures of everyday discrimination,^{3,4} loneliness,⁵ perceived stress,⁶ social support, ⁷ social cohesion, ⁸ medical discrimination, ⁹ and food insecurity ¹⁰ were evaluated in participants that completed the additional SDoH survey SDoH scales were constructed based on Tesfaye et al¹¹
- Clinical comorbidities were identified using SNOMED codes from EHR data during the baseline period - Cardiovascular (CV) comorbidities were angina pectoris, atrial fibrillation, heart failure, myocardial infarction, cardiac arrest, coronary arteriosclerosis, hypertension, and stroke
- Cardiometabolic (CM) comorbidities were hyperlipidemia, type 2 diabetes mellitus, obesity, and metabolic encephalopathy
- Cardiorenal (CR) comorbidities were chronic kidney disease and hypertensive renal disease • Descriptive statistics were used to summarize participant demographics, SDoH factors, and clinical comorbidities
- Multivariable logistic regression analyses, adjusted for age at diagnosis, sex, time in EHR, race/ ethnicity, education, income, employment status, health insurance, and disability status, were conducted to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for having a CV, CM, or CR comorbidity, overall and separately


Results





- 1–2 mild, 3–4 moderate, and 5+ severe comorbidity burden associated with increased mortality risk. NHPI, Native Hawaiian or Pacific Islander; SD, standard deviation; USD, United States dollar.
- In total, 2766 participants (narcolepsy: n=694; non-narcolepsy: n=2072) were identified, with a mean age of 49.0 years; 70.3% were female; 57.2% were non-Hispanic White; and 20.3% were covered by Medicaid

course of this employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc. **B Hutchinson** is a consultant to Jazz Pharmaceuticals, plc.










^aCV comorbidities were angina pectoris, atrial fibrillation, heart failure, myocardial infarction, cardiac arrest, coronary arteriosclerosis, hypertension, and stroke. ^bCM comorbidities were hyperlipidemia, type 2 diabetes mellitus, obesity, and metabolic encephalopathy. °CR comorbidities were chronic kidney disease and hypertensive renal disease Cl. confidence interval; CM, cardiometabolic; CR, cardiorenal; CV, cardiovascular; EHR, electronic health record; OR, odds ratio.

- Participants with narcolepsy versus without narcolepsy had a higher prevalence of hypertension (48.7% vs 36.3%), heart failure
- (7.4% vs 2.8%), and obesity (32.1% vs 19.9%) Participants with narcolepsy also had higher odds (OR [95% CI]) of having a CV (1.76 [1.35, 2.28]), CM (2.12 [1.73–2.59]), or CR (2.47 [1.72-3.56]) comorbidity, and at least 1 CV/CM/CR comorbidity (2.15 [1.66, 2.79]) during the baseline period, compared with participants without narcolepsy



Conclusions

SD, standard deviation; SDoH, social determinants of health

social support and cohesion

 Narcolepsy is associated with social and clinical challenges, including employment barriers, SDoH-related disparities, and higher burden of comorbidities

• Among respondents who completed the additional SDoH survey (narcolepsy: n=259; non-narcolepsy: n=768), participants with narcolepsy

reported higher levels of food insecurity, loneliness, perceived stress, and everyday and medical discrimination, as well as lower levels of

- Limitations of the study include a small sample size, particularly for analyses that required completion of the additional SDoH survey
- Comprehensive and timely narcolepsy management strategies are warranted to address whole-person health, including comorbidities and social factors that may influence access to care and health outcomes

References: 1. American Academy of Sleep Medicine; 2023. 2. Denny JC, et al. N Engl J Med. 2019;381:668-76. 3. Williams DR, et al. Everyday Discrimination Scale. 2025. Available at: https://scholar.harvard.edu/davidrwilliams/node/32397. 5. Hays RD, DiMatteo MR. J Pers Assess. 1987;51:69-81. 6. Cohen S, et al. J Health Soc Behav. 1983;24:385-96. 7. Moser A, et al. J Clin Epidemiol. 2011;21:502-9. 10. Hager ER, et al. Pediatrics. 2010;126:e26-32. 11. Tesfaye S, et al. Scientific Reports. 2024;14:8815.

